TerminatedPhase 2NCT03884465
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Studying Heritable pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Liquidia Technologies, Inc.
- Principal Investigator
- Ardeschir Ghofrani, Prof. MD.Universitatskinikum Giessen und Marburg GmbH
- Intervention
- Inhaled dry powder treprostinil (LIQ861)(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2020
Study locations (3)
- CHRU de Nancy, Nancy, Vandoeuvre Les Nancy, France
- CHU de Bicetre, Le Kremlin-Bicêtre, France
- Studienambulanz fur Pulmonale Hypertonie at Medizinishe Klinik II, Universitatskinikum Giessen und Marburg GmbH, Giessen, Germany
Collaborators
FGK Clinical Research GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03884465 on ClinicalTrials.govOther trials for Heritable pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06850792imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNceUniversity of Sao Paulo General Hospital
- ACTIVE NOT RECRUITINGNCT06587074Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific TherapyRussian Cardiology Research and Production Center
- RECRUITINGNCT05462574Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)Vanderbilt University Medical Center
See all trials for Heritable pulmonary arterial hypertension →